Derek DiRocco - 13 Jun 2023 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Reporting relationship: Director
Issuer ticker: ITOS
Reported as of: 13 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2023, 19:53:23 UTC
Prior SEC filing: 13 Feb 2023
Next SEC filing: 23 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Adi Osovsky, as Attorney-in-Fact

Key filing fact

Derek DiRocco filed Form 4 for iTeos Therapeutics, Inc. (ITOS) on 15 Jun 2023.

Key facts

This page summarizes Derek DiRocco's Form 4 filing for iTeos Therapeutics, Inc. (ITOS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2023, 19:53.

Change

Previous filing in this sequence was filed on 13 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ITOS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +22,383
Change %
Price: $0.000000
Shares after: 22,383
Date: 13 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,383
Exercise price: $14.77
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.